Boldenone undecylenate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Boldenone undecylenate
Accession Number
DB14639  (DBSALT001616)
Type
Small Molecule
Groups
Illicit, Vet approved
Description
Not Available
Structure
Thumb
Synonyms
  • 17beta-Hydroxyandrosta-1,4-dien-3-one 10-undecenoate
  • Boldenone 10-undecenoate
External IDs
BA 29038 / BA-29038 / BRN 2402671
Active Moieties
NameKindUNIICASInChI Key
Boldenoneprodrug5H7I2IP58X846-48-0RSIHSRDYCUFFLA-DYKIIFRCSA-N
Categories
UNII
ZS6D2ITA30
CAS number
13103-34-9
Weight
Average: 452.679
Monoisotopic: 452.329045277
Chemical Formula
C30H44O3
InChI Key
AHMMSNQYOPMLSX-CNQKSJKFSA-N
InChI
InChI=1S/C30H44O3/c1-4-5-6-7-8-9-10-11-12-28(32)33-27-16-15-25-24-14-13-22-21-23(31)17-19-29(22,2)26(24)18-20-30(25,27)3/h4,17,19,21,24-27H,1,5-16,18,20H2,2-3H3/t24-,25-,26-,27-,29-,30-/m0/s1
IUPAC Name
(1S,3aS,3bR,9aR,9bS,11aS)-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl undec-10-enoate
SMILES
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2OC(=O)CCCCCCCCC=C

Pharmacology

Indication
Not Available
Pharmacodynamics

The activity of boldenone is mainly anabolic, with a low androgenic potency. The drug is commonly used in doping within bodybuilding, even though this use is illegal. If intended to assist in bodybuilding, the drug is taken as part of a steroid stack of other anabolic steroids, usually with a potent androgen like testosterone as the 'base' of the stack. Boldenone is an androgen that differs from 17b-testosterone (17b-T) by only one double bond at the 1-position, and the removal of the methyl group protecting the 17-OH group allows it to be orally active.

Mechanism of action

Boldenone is a steroid hormone which has androgenic activity. Androgens bind to the androgen receptor, which regulates gene transcription.

TargetActionsOrganism
AAndrogen receptorNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

14 days

Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AlclometasoneThe risk or severity of edema formation can be increased when Boldenone undecylenate is combined with Alclometasone.
AmcinonideThe risk or severity of edema formation can be increased when Boldenone undecylenate is combined with Amcinonide.
BetamethasoneThe risk or severity of edema formation can be increased when Boldenone undecylenate is combined with Betamethasone.
Clobetasol propionateThe risk or severity of edema formation can be increased when Boldenone undecylenate is combined with Clobetasol propionate.
DesoximetasoneThe risk or severity of edema formation can be increased when Boldenone undecylenate is combined with Desoximetasone.
FludrocortisoneThe risk or severity of edema formation can be increased when Boldenone undecylenate is combined with Fludrocortisone.
FlunisolideThe risk or severity of edema formation can be increased when Boldenone undecylenate is combined with Flunisolide.
Fluocinolone acetonideThe risk or severity of edema formation can be increased when Boldenone undecylenate is combined with Fluocinolone acetonide.
FluorometholoneThe risk or severity of edema formation can be increased when Boldenone undecylenate is combined with Fluorometholone.
FlurandrenolideThe risk or severity of edema formation can be increased when Boldenone undecylenate is combined with Flurandrenolide.
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
10128605
ChEMBL
CHEMBL2106059
Wikipedia
Boldenone_undecylenate

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility5.54e-05 mg/mLALOGPS
logP6.27ALOGPS
logP7.76ChemAxon
logS-6.9ALOGPS
pKa (Strongest Acidic)18.39ChemAxon
pKa (Strongest Basic)-5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area43.37 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity136.15 m3·mol-1ChemAxon
Polarizability56.18 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Steroid esters
Direct Parent
Steroid esters
Alternative Parents
Androgens and derivatives / 3-oxo delta-1,4-steroids / Delta-1,4-steroids / Cyclic ketones / Carboxylic acid esters / Monocarboxylic acids and derivatives / Organic oxides / Hydrocarbon derivatives
Substituents
Steroid ester / Androgen-skeleton / Androstane-skeleton / Oxosteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / Delta-1,4-steroid / Cyclic ketone / Ketone / Carboxylic acid ester
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Zinc ion binding
Specific Function
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription ...
Gene Name
AR
Uniprot ID
P10275
Uniprot Name
Androgen receptor
Molecular Weight
98987.9 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Merlanti R, Gallina G, Capolongo F, Contiero L, Biancotto G, Dacasto M, Montesissa C: An in vitro study on metabolism of 17beta-boldenone and boldione using cattle liver and kidney subcellular fractions. Anal Chim Acta. 2007 Mar 14;586(1-2):177-83. Epub 2006 Dec 10. [PubMed:17386710]

Drug created on September 01, 2018 12:37 / Updated on October 01, 2018 15:47